By communicating with oncologists, Flatiron enhances their understanding of potential issues in clinics and how technology can enhance clinical workflow, said Bobby Green, MD, chief medical officer at Flatiron.
By communicating with oncologists, Flatiron enhances their understanding of potential issues in clinics and how technology can enhance clinical workflow, said Bobby Green, MD, chief medical officer at Flatiron.
Transcript
How important is it for Flatiron to collaborate with oncologists who are at the forefront of care to better understand what features should be included to enhance clinical workflow?
So, if I’ve learned nothing in my 5 plus years at Flatiron, is that you really don’t know what the right things to do are unless you actually talk to the people who are doing it and go spend time with them. So, at Flatiron what that means is talking to oncologists, asking them questions, understanding what their pain points are, going to their clinics, observing what actually happens while they’re seeing patients, and we do a ton of that at Flatiron. We have teams that go out and spend time with practices and understand their workflows. It’s just 1 of those things that there’s no right answer. Different practices do things differently, so you have to assimilate that information and use that sort of frontline experience to better understand—how do you use technology to solve those problems.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More